Indirect Comparison Associates Zanubrutinib With Improved PFS in Treatment-Naive CLL | OncLive In a post hoc indirect comparison, data showed zanubrutinib was linked with improved PFS vs acalabrutinib/venetoclax in treatment-naive CLL.

In an indirect comparative analysis of the phase 3 SEQUOIA and AMPLIFY trials, zanubrutinib was associated with improved PFS vs acalabrutinib plus venetoclax in treatment-naive CLL.

Read more @fredhutch.org #leusm #oncology #OncClub www.onclive.com/view/indirec...

Retrospective data show up-front dose reductions of enfortumab vedotin lowered the risk of treatment interruptions without impeding OS in patients with advanced urothelial cancer receiving first-line enfortumab vedotin plus pembrolizumab #blcsm #oncology #OncClub www.onclive.com/view/enfortu...

Dr Shah on Disease-Related Exacerbation With ICIs in Patients With Cancer and Preexisting NAIDs Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.

WATCH: Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer. @nufeinbergmed.bsky.social @jamanetworkopen.com #OncClub #oncology
www.onclive.com/view/dr-shah...

IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations MDS and AML.

IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML #mpnsm #leusm #oncology #OncClub www.onclive.com/view/ihc-tes...

Skipping Surgery in Early HER2+ Breast Cancer or TNBC? Phase 2 Trial Data Highlight Feasibility of Selective Omission @mdanderson.bsky.social #bcsm #oncology #OncClub www.onclive.com/view/skippin...

Thank you @onclive.bsky.social for this thorough review of our recent clinical trial for patients with metastatic GI cancers. Looking forward to more #GICancer #OncClub discussions to follow over the next few days at #ASCO25!
@thelancetoncol.bsky.social: www.sciencedirect.com/science/arti...

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors
#GICancer @cancerassassin1.bsky.social #OncClub
www.onclive.com/view/neoanti...

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML #OncClub #leusm #oncology www.onclive.com/view/venetoc...

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma @upmcnews.bsky.social #OncClub #sarcoma www.onclive.com/view/pembrol...